Cargando…

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for patients with CD19(+) B-cell malignancies. Combination strategies that improve CAR T-cell potency, limit tumor environment–mediated immune dysfunction, and directly reduce tumor burden may increase the potential for durable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Jim S., Johnstone, Timothy G., Baturevych, Alex, Hause, Ronald J., Ragan, Seamus P., Clouser, Christopher R., Jones, Jon C., Ponce, Rafael, Krejsa, Cecile M., Salmon, Ruth A., Ports, Michael O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Basic Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144752/ https://www.ncbi.nlm.nih.gov/pubmed/31899702 http://dx.doi.org/10.1097/CJI.0000000000000307

Ejemplares similares

Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel
por: Olson, N. Eric, et al.
Publicado: (2023)

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
por: Abramson, Jeremy S., et al.
Publicado: (2022)

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL
por: Mirza, Abu-Sayeef, et al.
Publicado: (2023)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2022)

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2022)

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
por: Abramson, Jeremy S., et al.
Publicado: (2023)

Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2021)

Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
por: Ogasawara, Ken, et al.
Publicado: (2021)

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
por: Cartron, Guillaume, et al.
Publicado: (2022)

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL
por: Rasheed, Yusuf, et al.
Publicado: (2023)

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
por: Series, Jennifer, et al.
Publicado: (2019)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
por: Bye, Alexander P., et al.
Publicado: (2022)

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
por: Parker, Christopher, et al.
Publicado: (2023)

Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis
por: Tuomi, Jari M., et al.
Publicado: (2021)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
por: Zhu, Sining, et al.
Publicado: (2021)

P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY
por: Gordon, L. I., et al.
Publicado: (2022)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
por: Zhu, Sining, et al.
Publicado: (2021)

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB
por: Shadman, Mazyar, et al.
Publicado: (2023)

Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
por: Morell, Anselm, et al.
Publicado: (2020)

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
por: Estupiñán, H. Yesid, et al.
Publicado: (2021)

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
por: Lu, Xiaoxiao, et al.
Publicado: (2023)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study
por: Izutsu, Koji, et al.
Publicado: (2021)

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
por: Harrington, Bonnie K., et al.
Publicado: (2016)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023)

Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia
por: Delgado, Julio, et al.
Publicado: (2019)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia
por: Izzedine, Hassan, et al.
Publicado: (2022)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_brstc8c1jeotrtjg1902d02d2e